Instem plc Investor Presentation
27 Octubre 2020 - 1:00AM
RNS Non-Regulatory
TIDMINS
Instem plc
27 October 2020
Instem plc
("Instem" or "the Company")
Investor Presentation
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, will be hosting a presentation through
the digital platform, Investor Meet Company, at 16.30 on the
afternoon of 04 November 2020.
The Company will discuss recent results, where it provided an
update on trading and progress on its acquisition strategy
following the July 2020 fundraise. It will also discuss divisional
developments, specifically within the areas of Informatics and SEND
(the Standard for the Exchange of Non-clinical Data). No new price
sensitive information will be provided.
Questions can be submitted pre-event to instem@walbrookpr.com or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. Responses to the Q&A from the
live presentation will be published at the earliest opportunity on
the IMC platform.
Investors can sign up to Investor Meet Company for free and add
to meet Instem via the following link
https://investormeetcompany.com/instem-plc/register-investor
Those investors who have already registered with Investor Meet
Company will automatically be invited.
A copy of the presentation will be made available on the
Company's website shortly after the presentation.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management and Data Collection; Regulatory Solutions for
Submissions and Compliance; and Informatics-based Insight
Generation.
Instem solutions are in use by over 500 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform at some stage of their
development.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUNORRRVURUUA
(END) Dow Jones Newswires
October 27, 2020 03:00 ET (07:00 GMT)
Instem (LSE:INS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Instem (LSE:INS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024